This technology is a set of transgenic zebrafish lines expressing hallmark proteins of Alzheimer’s disease with similar pathology to human brains for use as a tool in early drug development.
Alzheimer’s disease is a neurodegenerative disorder affecting millions of people globally, but treatments for this debilitating disease remain inadequate. Accurate animal models are essential for understanding disease mechanisms and early drug development, but existing in vivo models do not sufficiently recapitulate human pathologies. A more accurate animal system that mimics human Alzheimer’s disease conditions would advance understanding of this disorder and promote more efficient drug screening toward better therapies.
This technology introduces zebrafish lines including multiple variations of genetic modifications expressing amyloid beta 42 and Tau, two hallmark proteins of Alzheimer’s disease, in relevant cell types. These animal models display basic biochemical alterations similar to those in human Alzheimer’s disease patients, thus presenting a tool for Alzheimer’s disease research with more accurate pathologies.
These zebrafish lines have been validated in vivo and compared to human Alzheimer’s disease cohort datasets.
IR CU23304
Licensing Contact: Sara Gusik